Cocrystal Pharma (COCP) Current Deferred Revenue (2017 - 2018)
Cocrystal Pharma (COCP) reported Current Deferred Revenue of $3000.0 for Q4 2018, down 90.32% on a YoY basis from $31000.0 in Q4 2017, and down 90.32% sequentially from $31000.0 in Q4 2017.
Cocrystal Pharma (COCP) Current Deferred Revenue (2017 - 2018) Analysis & Trends
Cocrystal Pharma (COCP) has 2 years of Current Deferred Revenue data on file, last reported at $3000.0 in Q4 2018.
- For the quarter ending Q4 2018, Current Deferred Revenue fell 90.32% year-over-year to $3000.0; the trailing twelve-month figure through Dec 2018 stood at $3000.0 (down 90.32% YoY), and the FY2018 full-year result was $3000.0, down 90.32% from the prior year.
- Current Deferred Revenue eased to $3000.0 in Q4 2018, from $31000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $31000.0 in Q4 2017 to a low of $3000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Cocrystal Pharma | 12.57 Mn | 7.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 3,000.00 |
| Dec 31, 2017 | 31,000.00 |